Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Virologic, immunologic and clinical impact of lamivudine in HIV-1 patients with M184V/I mutation and treatment failure
2005-000028-17Phase 4Active
- Sponsor
- DAVID DALMAU
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by DAVID DALMAU. Primary endpoints: Virologic suppression at 24 weeks, Virologic suppression at 48 weeks and 1 more. Started Apr 2006; status: active.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-000028-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000028-17.